Stereotactic Body Radiotherapy for Pancreatic Cancer
CL Chiang, CSY Yeung, MYP Wong, VWY Lee, VHF Lee, FAS Lee, FCS Wong
Hong Kong J Radiol 2017;20:303-11
DOI: 10.12809/hkjr1716861
Despite advances in surgical, radiation and systemic therapy, the prognosis of pancreatic cancer remains poor. Most patients are not amendable to curative surgical resection at presentation. Chemo-radiotherapy is the standard of care for locally advanced pancreatic cancer, but its local control is poor. Stereotactic body radiotherapy (SBRT) is a viable therapeutic option to maximise local control with a tolerable side-effect profile. It enables precise delivery of high-dose radiation over a short period (typically 1-5 days) and leads to better local control, disease outcome, and symptom palliation. SBRT can also be applied in neoadjuvant, adjuvant, or re-irradiation treatment. We review the technology, clinical application, and future direction of SBRT for treatment of pancreatic cancer.
Authors' affiliations:
CL Chiang1,2,3, CSY Yeung3, MYP Wong4, VWY Lee3, VHF Lee1,2, FAS Lee3, FCS Wong3
1Department of Clinical Oncology, The University of Hong Kong, Pokfulam, Hong Kong
2Department of Clinical Oncology, The University of Hong Kong–Shenzhen Hospital, Shenzhen, China
3Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong
4Department of Medical Physics, Tuen Mun Hospital, Tuen Mun, Hong Kong
中文摘要
胰腺癌的立體定向放射治療
蔣子樑、楊善如、黃然柏、李蘊恩、李浩勳、李安誠、黃志成
雖然手術、放療和全身治療有所進步，但胰腺癌的預後仍然很差。大多數患者在入院時無法耐受手術切除。化放療是局部晚期胰腺癌的標準治療方案，但局部控制較差。立體定向放射治療（SBRT）是能提供最大局部控制的可行選擇，而其副作用是可耐受的。它能夠在短時間內（通常為1-5天）精確地輸送高劑量輻射，並導致更好的局部控制、疾病結果和症狀緩解。SBRT也可用於新輔助治療、輔助治療或再照射治療。我們回顧SBRT治療胰腺癌的技術、臨床應用和未來發展方向。